Ther Hervaxx ph1b trial was open label. We know the results. What the market is waiting for is an update on that trial. Gastric Canver prognosis is normally 6 months to live after diagnosis. LC said last November , 7 months ago to expect an update in the next 3-6 months. She also said the longer we wait for that update the better the news will be. Put simply the longer we wait the longer the survival time will be.
Because this was open label IMU know exactly what the results are. It’s now a waiting game. But you can be certain this is good news. It rarely happens in Biotechs that you get such certainty of an outcome like this.
-
- There are more pages in this discussion • 30,563 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $179.4K | 14.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 15731879 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3463196 | 20 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |